BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+0.91%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.67B
AUM Growth
+$2.67B
(+0.03%)
Cap. Flow
+$85.3M
Cap. Flow
% of AUM
3.2%
Top 10 Holdings %
Top 10 Hldgs %
54.57%
Holding
76
New
9
Increased
18
Reduced
16
Closed
6
Top Buys
| 1 |
GH Research
GHRS
|
$202M |
| 2 |
argenx
ARGX
|
$103M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$39.9M |
| 4 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
$30.2M |
| 5 |
Janux Therapeutics
JANX
|
$29.4M |
Top Sells
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$239M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$61.3M |
| 3 |
IDEAYA Biosciences
IDYA
|
$61.3M |
| 4 |
CytomX Therapeutics
CTMX
|
$43.1M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$35.6M |
Sector Composition
| 1 | Healthcare | 98.39% |
| 2 | Financials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
GH Research
GHRS
$837M
| $202M | 7.55% | +9,275,156 | New | +$202M |
|
|
2
argenx
ARGX
$43.6B
| $196M | 7.35% | 651,204 +341,605 | +110% | +$103M |
|
3
Olema Pharmaceuticals
OLMA
$375M
| $186M | 6.99% | 6,661,503 | – | – |
|
4
Protagonist Therapeutics
PTGX
$3.67B
| $168M | 6.31% | 3,754,095 -205,356 | -5% | -$9.22M |
|
5
Merus
MRUS
$4.98B
| $153M | 5.75% | 7,285,071 | – | – |
|
6
Kymera Therapeutics
KYMR
$2.95B
| $128M | 4.78% | 2,630,658 | – | – |
|
7
Xoma
XOMA
$392M
| $120M | 4.5% | 3,530,543 | – | – |
|
8
Repare Therapeutics
RPTX
$71.7M
| $116M | 4.35% | 3,722,398 | – | – |
|
9
Relay Therapeutics
RLAY
$619M
| $108M | 4.03% | 2,938,202 +65,055 | +2% | +$2.38M |
|
10
Revolution Medicines
RVMD
$7.1B
| $78.9M | 2.96% | 2,485,049 -458,000 | -16% | -$14.5M |
|
11
Arcus Biosciences
RCUS
$1.13B
| $76.8M | 2.88% | 2,797,822 +921,700 | +49% | +$25.3M |
|
12
ESSA Pharma
EPIX
$11.4M
| $70M | 2.63% | 2,451,561 -456,765 | -16% | -$13M |
|
13
AC Immune
ACIU
$205M
| $67.8M | 2.54% | 8,545,179 +1,040,600 | +14% | +$8.25M |
|
14
4D Molecular Therapeutics
FDMT
$288M
| $48.3M | 1.81% | 2,005,862 +974,792 | +95% | +$23.5M |
|
15
Verastem
VSTM
$569M
| $45.9M | 1.72% | 11,286,258 -194,736 | -2% | -$793K |
|
|
16
Syndax Pharmaceuticals
SNDX
$1.41B
| $42.7M | 1.6% | 2,486,429 +2,322,905 | +1,421% | +$39.9M |
|
17
Lexicon Pharmaceuticals
LXRX
$400M
| $38.5M | 1.44% | 8,394,000 | – | – |
|
18
Replimune Group
REPL
$422M
| $35.3M | 1.32% | 918,928 +457,500 | +99% | +$17.6M |
|
|
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $35.1M | 1.32% | 3,094,174 | – | – |
|
20
Kura Oncology
KURA
$686M
| $34.1M | 1.28% | 1,635,112 | – | – |
|
|
RAIN
21
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $30.2M | 1.13% | +1,945,949 | New | +$30.2M |
|
22
Spero Therapeutics
SPRO
$116M
| $29.8M | 1.12% | 2,137,978 | – | – |
|
|
23
Janux Therapeutics
JANX
$1.37B
| $29.4M | 1.1% | +1,176,681 | New | +$29.4M |
|
|
24
Xenon Pharmaceuticals
XENE
$2.98B
| $29.3M | 1.1% | 1,571,778 -1,910,000 | -55% | -$35.6M |
|
|
PNT
25
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $28.5M | 1.07% | 2,772,226 +2,000,000 | +259% | +$20.6M |
|